SCHEDULE: Vanguard Discloses 5.09% Stake in Recursion Pharmaceuticals

Vanguard Capital Management has reported beneficial ownership of 26,744,129 shares, representing 5.09% of Recursion Pharmaceuticals Inc.'s common stock.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 26,744,129 shares of Recursion Pharmaceuticals Inc. common stock.
• This holding represents 5.09% of the total class of securities.
• The filing indicates that Vanguard Capital Management has sole power to dispose of or direct the disposition of all 26,744,129 shares.
• Vanguard also has sole voting power over 3,978,189 shares.
• The filing is made under Schedule 13G, indicating it is an informational filing by a passive investor.
• The reporting date for this ownership stake is June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates continued institutional support from a major player like Vanguard, but it is a routine ownership disclosure rather than a strategic announcement.

Positives

• Vanguard's increased stake suggests confidence in Recursion Pharmaceuticals' long-term prospects, potentially attracting further institutional investment.
• The passive nature of the filing (Schedule 13G) indicates Vanguard is not seeking to control the company, which can be viewed positively by existing management and shareholders.
• Vanguard's significant ownership (5.09%) provides a stable, long-term shareholder base.

Negatives

• The filing does not contain any negative information regarding Recursion Pharmaceuticals' operations or financial health.

Risks

• As a Schedule 13G filing, it signifies a passive investment. Any change in Vanguard's investment strategy could lead to significant stock sales, impacting share price.
• The company's reliance on future research and development success, as implied by its industry, presents inherent risks not detailed in this ownership filing.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance from Recursion Pharmaceuticals Inc.

Industry Context

StockSavvy.ai notes that significant institutional ownership, such as Vanguard's stake, is common in the biotechnology and pharmaceutical sectors, reflecting investor confidence in the potential for long-term growth and innovation.

Comparison to Industry Standards

• Vanguard's investment of 5.09% in Recursion Pharmaceuticals is a substantial stake, aligning with typical institutional holdings in mid-to-large cap biotechnology firms.
• Many biotechnology companies aim to attract diverse institutional investors like Vanguard, Fidelity, and BlackRock to ensure stable capital and market validation.

Stakeholder Impact

• Shareholders: The increased or maintained stake by a large institutional investor like Vanguard can be seen as a positive signal, potentially stabilizing or increasing investor confidence.
• Management: A significant passive investor like Vanguard generally supports existing management unless there are performance concerns.

Next Steps

• Vanguard Capital Management will continue to monitor its investment in Recursion Pharmaceuticals Inc.
• Recursion Pharmaceuticals Inc. will continue its business operations and research and development activities.

Key Dates

Keywords

Recursion Pharmaceuticals, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Shareholder